See the DrugPatentWatch profile for revatio
What does “Revatio” market size mean (and which market is usually counted)?
Revatio is the brand name for sildenafil used for pulmonary arterial hypertension (PAH). Market size can vary a lot depending on what analysts count: global vs. a specific country, “all sildenafil” vs. only Revatio-branded sales, and whether they measure prescription sales, total revenue, or patient numbers.
Global market size for Revatio (branded sildenafil for PAH)
I don’t have any provided source figures for Revatio’s market size (e.g., global sales/revenue, units, or patient volume), so I can’t give an evidence-based number.
What I can estimate from if you share one input
If you tell me one of the following, I can translate it into a market-size estimate framework:
- A target geography (e.g., US only, EU5, or worldwide)
- The measurement type (annual sales revenue vs. units vs. prescriptions)
- Any starting number you have (for example, “Revatio made about $X in 2023” or “PAH market is $Y and sildenafil share is Z%”)
Where to look next (common data sources)
For Revatio specifically, the most common market-size inputs come from:
- Prescription/sales databases (often for branded products and therapeutic indications)
- Company filings or investor materials (if the brand is disclosed separately)
- Market-research reports that break out the PAH treatment segment and the branded sildenafil portion
If you share what geography and year you care about (and whether you mean Revatio-branded sales or the broader PAH sildenafil market), I can help you pin down the right definition and what numbers to use.